Table 2.
Facilitators identified in the literature.
| Facilitators | Occurrences by article reference number | Total occurrences |
| Efficiency | 2,7,8,15,16,17,19,20,23,25,29,31,33 | 13 |
| Hospital sizea | 7,12,16,24,25,26,28,29,31,32 | 11 |
| Improved quality | 15,18,21,22,23,26,30,31,32,33 | 10 |
| Access to patient data | 8,10,15,19,20,22,28,29 | 8 |
| User perception/perceived usefulness | 5,7,9,21,22,26,30 | 7 |
| Ability to transfer information | 8,9,19,28,29,30 | 6 |
| Communication | 7,8,15,22,30 | 5 |
| Executive management support | 1,5,9,10,13 | 6 |
| Incentives | 2,16,21,23 | 5 |
| Error reduction | 8,19,31,32 | 4 |
| Time savings | 5,8,15,20 | 4 |
| Competivenessa | 7,10,13,27 | 4 |
| Security | 8,21,22 | 3 |
| Improved population health | 2,15,22 | 3 |
| Continuity of care document | 2,15,40 | 3 |
| Urban/more developed locations/statusa | 2,7,26 | 3 |
| Knowledge/IT management | 11,13,15 | 3 |
| Staff retention | 8,16 | 2 |
| Long run cost savings | 8,31 | 2 |
| Alignment with strategy | 1,13 | 2 |
| Project planning | 8 | 1 |
| Patient empowerment | 1 | 1 |
| Patient engagement | 14 | 1 |
| Effectiveness | 32 | 1 |
| Genome associated care | 31 | 1 |
aStatistical association identified through retrospective studies, rather than answers to “why” in a survey or interview.